Last updated 14 days ago

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

80 patients around the world

Available in Puerto Rico, Colombia

Merck Sharp & Dohme LLC

1Research sites

80Patients around the world

This study is for people with

Cirrhosis

Nonalcoholic cirrhosis

To 80 Years

All Gender

: Has compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis.
Has either type 2 diabetes that is controlled by diet or medication, or does not have type 2 diabetes.

: Has history of a liver disease other than MASH, for example, Hepatitis B or C, drug-induced liver disease, or autoimmune liver disease.
Has history of type 1 diabetes.
Had a bariatric surgical procedure less than 5 years before entry into the study.
History of pancreatitis.
Major illnesses like recent episodes of heart problems, such as congestive heart failure, unstable angina, heart attack, stroke, or mini-stroke.

Fundación Valle del Lili

Recruiting

Av. Simón Bolívar. Cra 98 # 18-49, Cali, Valle del Cauca

SponsorMerck Sharp & Dohme LLC

Study typeInterventional

Conditions

Nonalcoholic cirrhosis

Requirements

To 80 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06465186